Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans
| Status: | Completed |
|---|---|
| Conditions: | Endocrine, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 45 - 65 |
| Updated: | 4/25/2018 |
| Start Date: | March 2008 |
| End Date: | March 2015 |
Human aging is associated with increased fat mass, insulin resistance and systemic
inflammation. In addition to overall increases in fat mass, accumulation of lipid in such
insulin-sensitive tissues as liver and skeletal muscle appears to contribute importantly to
insulin resistance. Furthermore, age-related decreases in muscle mitochondrial ATP production
rate and mitochondrial DNA copy number are likely to contribute to impaired insulin-mediated
glucose disposal, as well as decreased muscular endurance and activity levels. Additionally,
systemic inflammation is now believed to contribute to insulin resistance and thus ultimately
to many age-related disorders, including diabetes mellitus, Alzheimer's disease,
atherosclerosis and many cancers.
inflammation. In addition to overall increases in fat mass, accumulation of lipid in such
insulin-sensitive tissues as liver and skeletal muscle appears to contribute importantly to
insulin resistance. Furthermore, age-related decreases in muscle mitochondrial ATP production
rate and mitochondrial DNA copy number are likely to contribute to impaired insulin-mediated
glucose disposal, as well as decreased muscular endurance and activity levels. Additionally,
systemic inflammation is now believed to contribute to insulin resistance and thus ultimately
to many age-related disorders, including diabetes mellitus, Alzheimer's disease,
atherosclerosis and many cancers.
The purpose of this research is to study the effects of a medication called resveratrol on
the body's response to insulin (a hormone to control blood sugar), on inflammation and/or on
specific cells and processes in fat tissue, and on skeletal muscle metabolism and on brain
function.
the body's response to insulin (a hormone to control blood sugar), on inflammation and/or on
specific cells and processes in fat tissue, and on skeletal muscle metabolism and on brain
function.
Inclusion Criteria:
- BMI: 26-35
- Non-smoker
- Normal screening labs (CMC, chemistry, LFTs PT/PTT)
- No CAD
- Good IV access
Exclusion Criteria:
- High cholesterol
- <4 week history of participation in another drug trial
- Severe hypertension
- Heart disease
- Liver disease of liver abnormalities
- Cerebrovascular disease, i.e. stroke
- CVD
- Seizures
- Bleeding disorders
- Muscle disease
- Cancer
- HIV
- Hepatitis (all types)
- Mentally disabled persons
- Pregnant women
- Allergies to Novocaine, Lidocaine, Benzocaine
- Subjects on the following medications:
- Anticoagulant and antiplatelet drugs
- Anti-epileptic drugs
- Mexiletene
- Quinidine
- Cyclosporine
- Tacrolimus
- HIV protease inhibitors
We found this trial at
1
site
Albert Einstein College of Medicine The Albert Einstein College of Medicine of Yeshiva University is...
Click here to add this to my saved trials
